Dacryocystitis Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

Dacryocystitis is an infection or inflammation of the lacrimal sac, typically resulting from nasolacrimal duct obstruction, and it is treated through a mix of antibiotics, probing procedures, balloon dacryoplasty, and dacryocystorhinostomy (DCR) surgery. The global market encompasses pharmaceuticals, surgical devices, stents, and diagnostic tools used by ophthalmologists and oculoplastic surgeons. Estimates for 2025 differ widely across published research, ranging from approximately $209 million to $1.35 billion, with a central figure near $0.68 billion at a CAGR of roughly 4.56%. No government statistical agency publishes standardized figures for this niche condition, so all sizing relies on private commercial research.

• •Most prevalent in infants (congenital nasolacrimal duct obstruction) and adults over 60.
• •Standard surgical treatment is dacryocystorhinostomy (DCR), performed externally or endonasally.
• •Estimates vary widely because some reports cover only drugs and devices, while others bundle surgical services.

Aging populations in North America, Europe, and East Asia are a primary growth engine, as age-related nasolacrimal duct obstruction raises the incidence of chronic dacryocystitis. Rising awareness of ocular health, broader insurance coverage for lacrimal surgery, and increased availability of specialist ophthalmic care in emerging markets are expanding the addressable patient base. Continued adoption of minimally invasive endoscopic and balloon-assisted techniques is shortening recovery times and making treatment accessible to older patients who are poor surgical candidates for external DCR.

• •Demographic aging is increasing the pool of patients with acquired nasolacrimal duct obstruction.
• •Endoscopic and balloon dacryoplasty techniques are replacing more invasive external procedures.
• •Improving access to ophthalmology specialists in Asia-Pacific and Latin America is broadening diagnosis and treatment rates.

The market segments by treatment type (pharmacological therapy, probing, balloon dacryoplasty, DCR surgery), by patient age (adult vs. pediatric), and by end user (hospitals, ophthalmic clinics, ambulatory surgical centers). By geography, North America and Europe together hold the largest revenue share, supported by high procedure volumes, established reimbursement, and concentrated ophthalmic device manufacturers. Asia-Pacific is the fastest-growing region, driven by large aging populations in China, Japan, and India, expanding private hospital networks, and rising per-capita healthcare spending.

• •Pharmaceuticals (antibiotics, anti-inflammatories) and DCR surgery account for the bulk of revenue.
• •North America leads in current revenue, while Asia-Pacific posts the strongest growth rate.
• •Pediatric congenital cases represent a meaningful but smaller sub-segment compared with adult acquired cases.

What are the recent trends and outlook?

The near-term outlook is shaped by a shift toward endoscopic endonasal DCR, which offers no external scarring and faster recovery, and by continued adoption of silicone intubation and balloon catheter technologies. Pipeline activity includes refinement of drug-eluting lacrimal stents and antibiotic regimens tailored to resistant organisms commonly seen in chronic cases. Over the forecast horizon, the market is expected to grow steadily in line with global healthcare spending, with upside from earlier diagnosis through tele-ophthalmology and from expanding insurance coverage in middle-income countries.

• •Endonasal DCR is gaining share against external DCR due to cosmetic and recovery advantages.
• •Drug-eluting lacrimal stents and targeted antibiotic regimens are the most visible pipeline innovations.
• •Tele-ophthalmology is improving earlier diagnosis, particularly in underserved and rural regions.